1217190-38-9 Usage
Uses
Used in Pharmaceutical Industry:
2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 5-hydroxy-, phenylMethyl ester is used as a pharmaceutical candidate for its potential therapeutic properties. The heterocyclic structure and phenylmethyl ester group may contribute to its interaction with biological targets, offering potential benefits in drug development.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 5-hydroxy-, phenylMethyl ester serves as a chemical intermediate. Its unique structure and functional groups can be utilized in the synthesis of more complex molecules, contributing to the advancement of chemical research and the development of new compounds with various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1217190-38-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,7,1,9 and 0 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1217190-38:
(9*1)+(8*2)+(7*1)+(6*7)+(5*1)+(4*9)+(3*0)+(2*3)+(1*8)=129
129 % 10 = 9
So 1217190-38-9 is a valid CAS Registry Number.
1217190-38-9Relevant articles and documents
IMIDAZOLE DERIVATIVES
-
Page/Page column 98-99, (2013/02/27)
Described herein are compounds of formula (I), The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof
-
Page/Page column 65-66, (2011/04/18)
Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as, e.g., histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical compositions containing the compounds and their methods of use are also provided herein.
